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Background: Pathological complete remission of advanced stage rectal adenocarcinoma by chemotherapy alone is
rare. A case of advanced stage, low-lying rectal adenocarcinoma in which a complete response to treatment was
obtained with mFOLFOX6 and panitumumab (Pmab) is reported.
Case presentation: A 53-year-old man was referred to Shiga University of Medical Science hospital Shiga, Japan,
complaining of bloody stool. Gastrointestinal endoscopy was performed, and advanced stage rectal adenocarcinoma
was diagnosed. Computed tomography (CT) revealed regional lymph node metastases in the mesorectum.
Neoadjuvant chemotherapy (NAC) with mFOLFOX6 and Pmab was planned.
Endoscopy following four courses of chemotherapy revealed that the rectal cancer had been markedly reduced, and
the results of biopsies of the rectal tumor were negative for cancer. On CT, the mesorectal lymph node metastases had
disappeared. Total intersphincteric resection (ISR) with a handsewn coloanal anastomosis was performed. Histological
examination showed a complete response to mFOLFOX6 and Pmab in advanced stage rectal cancer.
Conclusion: The result seen in this case suggests that short-term NAC with mFOLFOX6 and Pmab was effective for
low-lying rectal adenocarcinoma.
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In Western countries, the standard treatment for advanced
stage rectal cancer is neoadjuvant chemoradiotherapy
(CRT) followed by surgery [1]. On the other hand, curative
surgery including lateral lymph node dissection followed
by adjuvant chemotherapy is the standard treatment for
advanced rectal cancer in Japan [2]. Recently, neoadjuvant
CRT followed by anus-preserving surgery has also been re-
ported in Japan [3]. However, it was reported that postop-
erative anal function was decreased when the effect of
preoperative CRT was strong in patients treated with
intersphincteric resection (ISR) [3]. Use of panitumumab
(Pmab) and cetuximab (Cmab), anti-endothelial growth
factor receptor (EGFR) antibodies, has resulted in earlier
tumor shrinkage for K-ras wild type metastatic colorectal
cancer [4]. The case of a 53-year-old man with stage III* Correspondence: hirosono@belle.shiga-med.ac.jp
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reproduction in any medium, provided the orlow rectal cancer who had a complete response to neoad-
juvant oxaliplatin, 5-fluorouracil (5-FU) and l-folinic acid
(mFOLFOX6) and Pmab chemotherapy without concur-
rent radiotherapy is reported.
Case presentation
A 53-year-old man was referred to Shiga University of
Medical Science hospital, Shiga, Japan, complaining of
bloody stool. The patient was diagnosed as having a 3 cm
in length, type 2K-ras wild type rectal cancer, 2 cm from
the anal verge (Figure 1a) that invaded to the dentate line
(Figure 1b) on screening colonoscopy. Computed tomog-
raphy (CT) revealed rectal wall thickening and a regional
lymph node metastasis in the mesorectum (Figure 2a).
Advanced stage, low-lying rectal cancer was diagnosed.
We usually perform abdominoperineal resection (APR)
for advanced rectal cancer located in the anal canal as
in this case. However, the patient was not willing to
undergo APR.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Colonoscopy images. (a) Colonoscopy imaging shows a 3 cm in length, type 2 rectal cancer (b) that invades to the dentate line. (c) Repeated
colonoscopy after chemotherapy shows an excellent response with only injected mucosal scar in the area of the previously identified rectal cancer.
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CRT may adversely affect anorectal function [5]. It has
also been reported that Cmab and Pmab-containing
chemotherapy enables early tumor shrinkage [4]. For these
reasons, neoadjuvant chemotherapy (NAC) with mFOL-
FOX6 and Pmab was performed every 2 weeks with the
patient’s written, informed consent. The patient received a
total of four cycles of chemotherapy over 2 months.
Repeated colonoscopy after chemotherapy showed an ex-
cellent response with only injected mucosal scar in the area
of the previously identified rectal cancer (Figure 1c). The re-
sults of the biopsies were negative for cancer cells. Addition-
ally, CT scan demonstrated no rectal wall thickening and no
mesorectal lymph node metastasis (Figure 2b). The patient
underwent total ISR with a handsewn coloanal anastomosis,
total mesorectal and bilateral pelvic lymph node dissection,
and temporary loop ileostomy 3 weeks after completion of
NAC. No residual carcinoma was found (Figure 3), 12 non-
involved lymph nodes were identified, and all margins were
negative for cancer on histologic examination.
5-FU-based adjuvant chemotherapy after neoadjuvant
CRT followed by surgery is the standard treatment for
clinical stage III rectal cancer [1]. For this reason, the pa-
tient received adjuvant chemotherapy with tegafur-uracil
(UFT) and leucovorin administration for 3 months after
surgery. Three months after surgery, the patient is alive
without evidence of recurrence of cancer.Figure 2 Computed tomography (CT) images. (a) CT imaging reveals rectal w
(b) CT scan after chemotherapy demonstrates no rectal wall thickening and no mDiscussion
Preoperative 5-FU-based concurrent CRT followed by sur-
gery is the standard strategy for advanced rectal cancer in
Western countries [1]. However, it has been suggested
that preoperative CRT is strongly associated with postop-
erative complications, including anastomotic leakage [6]
and poor anal function, after low anterior resection and
ISR [3]. It has been reported that preoperative CRT also
increases late complications such as sexual and voiding
dysfunctions [7], intestinal and defecation problems [8],
and secondary carcinogenesis [9]. All of these have re-
cently become issues in Western countries.
Recently, new anticancer agents have markedly improved
the response rate and prognosis of unresectable and recur-
rent colorectal cancer. Oxaliplatin-based combination
chemotherapy improves survival of colorectal cancer pa-
tients in the metastatic and adjuvant settings [10-12].
Oxaliplatin-containing ‘induction chemotherapy’ before
CRT is associated with an objective response rate of up to
88% and rapid symptomatic improvement [13,14]. These
regimens may also convert unresectable liver metastases to
resectable ones [15,16]. It has been reported that bevacizu-
mab (Bmab), an anti-vascular endothelial growth factor
(VEGF) receptor antagonist, added to oxaliplatin-based
chemotherapy, capecitabine plus oxaliplatin (XELOX), re-
sulted in a high response rate for patients with colorectal
liver metastases [17]. In Japan, a multicenter phase II trialall thickening and a regional lymph node metastasis in the mesorectum.
esorectal lymph node metastasis. CT, computed tomography.
Figure 3 No residual carcinoma is found on histologic examination.
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cancer is now ongoing [18]. In addition, two retrospective
studies have shown that the early dimensional reduction of
target lesions after 6 weeks from the beginning of treat-
ment is an indicator of sensitivity to Cmab [19,20]. Pmab, a
fully human immunoglobulin G (IgG) anti-EGFR antibody,
has been considered equally effective in patients with K-ras
wild type refractory metastatic colorectal cancer. Cmab
must be administered every week, while Pmab can be ad-
ministered every 2 weeks.
In the neoadjuvant setting, surgery must be delayed for
at least 1 month after the last Bmab-containing chemo-
therapy. However, it is not necessary to delay surgery after
anti-EGFR-containing chemotherapy. Because of these
reasons, we considered that preoperative mFOLFOX6 and
Pmab chemotherapy should be effective for this case. Re-
cently, Li et al. reported a case of advanced rectal cancer
demonstrating a pathologic complete response after NAC
with six cycles of FOLFOX7 [21]. This case is the first re-
port in the English literature from an Asian country dem-
onstrating a pathological complete response after NAC in
a patient with low-lying advanced rectal cancer. In the
present case, NAC was given for four cycles, but the ap-
propriate period of NAC administration has not been de-
termined. However, a pilot study demonstrated clear
downstaging of primary colon cancer with only three cy-
cles of NAC [22]. Another report showed that detection,
by week 2 magnetic resonance imaging, of tumor shrink-
age >10% in response to therapy with Cmab or Pmab for
metastatic colorectal cancer represents an early indicator
of clinical outcome because it is predictive of the pro-
longation of progression-free survival and overall survival
[4]. We thought that if NAC was not effective, the patientwould not be able to receive curative surgery because of
disease progression. Therefore, we evaluated the efficacy
of NAC after a short course (four cycles) of chemotherapy.
We then decided to perform surgery because of the excel-
lent response to NAC. The present case suggests that
Pmab is a good candidate for NAC because of its earlier
drug response. We consider NAC is a promising pre-
operative treatment for locally advanced rectal cancer in-
stead of neoadjuvant CRT. However, there are no data
about whether NAC with or without concurrent radio-
therapy is effective against advanced rectal cancer. Further
studies are needed.
Conclusions
This case suggests that mFOLFOX6 and Pmab chemo-
therapy without irradiation may be an alternative therapy
for patients with low-lying rectal cancer.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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